多索茶碱联合盐酸氨溴索治疗老年稳定期COPD的临床疗效及对血清IL-33/sST2轴表达的影响
作者: |
1潘萍
1 无锡市锡山人民医院/东南大学附属中大医院无锡分院全科医学科,江苏 无锡214000 |
通讯: |
潘萍
Email: panpingwuxi@163.com |
DOI: | 10.3978/j.issn.2095-6959.2022.09.007 |
摘要
Clinical efficacy of doxofylline combined with ambroxol hydrochloride in the treatment of elderly patients with stable COPD and its effect on the expression of serum IL-33/sST2 axis
CorrespondingAuthor: PAN Ping Email: panpingwuxi@163.com
DOI: 10.3978/j.issn.2095-6959.2022.09.007
Abstract
Objective: To investigate the clinical efficacy of doxofylline combined with ambroxol hydrochloride in the treatment of elderly patients with stable chronic obstructive pulmonary disease (COPD) and its effect on the expression of serum IL-33/sST2 axis. Methods: A total of 110 elderly patients with stable COPD who were admitted to the outpatient clinic of Xishan People’s Hospital of Wuxi from January 2020 to January 2022 were selected and randomly divided into the control group and the experimental group, with 55 cases in each group. The control group was given doxofylline alone, and the experimental group was given doxofylline combined with ambroxol hydrochloride. The clinical efficacy, lung function, IL-33, sST2 mRNA and protein expression levels, serum inflammatory factor levels and incidence of adverse reactions were compared between the 2 groups before and after the treatment. Results: The total effective rate in the experimental group was 94.55% (52/55), which was higher than 74.55% (41/55) in the control group (P<0.05). After 14 days of treatment, the levels of forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), FEV1/FVC, and peak expiratory flow (PEF) in the experimental group were (1.97±0.28) L, (3.50±0.37) L, 0.74±0.10, (3.53±0.52) L/s, which were higher than those in the control group (all P<0.05). After 14 days of treatment in the experimental group, the mRNA expression levels of IL-33 and sST2 were (1.20±0.24) and (1.10±0.19), respectively, and the protein levels of IL-33 and sST2 were (382.07±35.40) pg/mL, (567.37±0.19) pg/mL, all lower than the control group (all P<0.05). The levels of IL-6, IL-8, CRP and TNF-α in the experimental group after 14 days of treatment were (5.94±0.98) ng/L, (251.06±12.28) ng/L, (4.71±0.92) mg/L, (11.98±2.12) pg/L, all lower than the control group (all P<0.05). The total adverse reaction rate in the experimental group was 7.27% (4/55), which was lower than 21.82% (12/55) in the control group (P<0.05). Conclusion: Doxofylline combined with ambroxol hydrochloride is effective in the treatment of elderly patients with stable COPD, can improve lung function, inhibit the expression level of serum IL-33/sST2 axis, reduce the level of inflammatory factors, and has few adverse reactions, which is safe and reliable.